Showing results (1361-1370 of 1,434) with videos related to
Sort By:
Pageof 144
European Journal of Human Genetics : EJHG|January 5, 2021
A synonymous variant in MYO15A enriched in the Ashkenazi Jewish population causes autosomal recessive hearing loss due to abnormal splicingYoel Hirsch, Chayada Tangshewinsirikul, Kevin T Booth, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 7, 2021
Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing lossMayher J Patel, Marina T DiStefano, Andrea M Oza, et al.Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.Gynecologic Oncology|August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinomaNicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.Journal of Cardiovascular Electrophysiology|July 14, 2025
Isoproterenol for Unmasking Dormant Conduction and Non-Pulmonary Vein Triggers During Atrial Fibrillation Ablation: Prospective Multicenter StudySaumil R Oza, Daniela Hincapie, Manasvi Gupta, et al.Frontiers in Global Women'S Health|March 7, 2024
A consensus statement on perinatal mental health during the COVID-19 pandemic and recommendations for post-pandemic recovery and re-buildLeanne Jackson, Mari Greenfield, Elana Payne, et al.Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.Cancer Discovery|November 15, 2018
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.Pageof 144